Database Query Results : Magnetic Field Rotating, , TumCI

MFrot, Magnetic Field Rotating: Click to Expand ⟱
Features:
Rotary Magnetic field can be generated by a spinning magnet or magnets. Or it can be implemented with 2 or more coils, power with a phase shift between them (90 deg for 2 coil implementation) (60deg for 3 coil implementation)
Targets affected are mostly the same as for Magnet fields
Main differences
- may enhance the EPR effect allowing targeting of drugs to cancer cells
- acts as wireless stirrer, especially on magnetic particles(inducing eddy currents in water media)
- research for use in nano surgery, and mechanical destruction of cancer cells
- continue to highlight ability to raise ROS in cancer cell and lower ROS in normal cells
- RMF may be responsible for Ca2+ distribution to pass across the plasma membrane(differental affected for cancer and normal cells)

Pathways:
- induce ROS production in cancer cells, while decreasing ROS in normal cells. Ca2+ is critical and the Ca2+ balance is increased in cancer cells while decreased in normal cells (example for wound healing)
- ROS↑ related: MMP↓(ΔΨm), Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, RhoA↓, NF-κB↓, TGF-β↓, ERK↓
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, ERK↓,
- Others: PI3K↓, AKT↓, Wnt↓, AMPK, ERK↓, JNK,
- Synergies: < Others(review target notes), Neuroprotective, Cognitive,

- Selectivity: Cancer Cells vs Normal Cells

Rotating Magnetic Fields
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS (tumor-selective oxidative stress) ↑ ROS (P→R); sustained to cytotoxicity (G) ↔ minimal change or transient ↑ without injury (P→R) P, R, G Primary stress amplifier Oncomagnetic reports emphasize selective tumor ROS increase with normal-cell sparing in comparable exposure conditions
2 Mitochondrial ETC inhibition (Complex I/NADH:ubiquinone) ↓ Complex I / respiration (P→R) ↔ limited effect (P→R) P, R Bioenergetic collapse trigger Rotating/spinning fields are proposed to disrupt mitochondrial electron flow, driving ROS elevation upstream of ΔΨm loss
3 Ca²⁺ signaling (ER–mitochondria Ca²⁺ transfer / mitochondrial Ca²⁺ load) ↑ Ca²⁺ dysregulation (P→R) contributing to mitochondrial failure (G) ↔ buffered Ca²⁺ homeostasis (P→R) P, R, G Amplifies ETC/ROS-driven toxicity RMF-driven mitochondrial stress can propagate via Ca²⁺ transfer to accelerate ΔΨm loss and pro-death ER stress in tumor cells while sparing normal cells
4 Mitochondrial permeability transition pore (MPTP) ↑ sustained MPTP opening (R→G) ↔ resistant to opening P, R, G Mitochondrial point-of-no-return RMF-enhanced ROS and Ca²⁺ loading promote persistent MPTP opening in tumor mitochondria, driving energetic collapse and apoptosis while normal cells remain below the opening threshold
5 ΔΨm / mitochondrial membrane integrity ↓ ΔΨm (R); progresses (G) ↔ preserved R, G Mitochondrial failure threshold Matches the “energy factory” targeting concept described in Oncomagnetic mechanism narratives
6 GSH depletion ↓ GSH (R→G) ↔ maintained R, G Loss of redox buffering Cancer-selective inability to restore GSH is a key discriminator vs normal cells
7 NRF2 response (selectivity gate) ↔ delayed/insufficient NRF2 (R→G) ↑ NRF2 (R→G) R, G Adaptive protection Normal-cell sparing is consistent with competent NRF2-driven antioxidant defense
8 ER stress / UPR (CHOP commitment) ↑ ER stress (R); CHOP/apoptotic UPR (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis failure ETC/ROS stress propagates to ER; commitment vs resolution diverges by cell robustness
9 DNA damage (oxidative; checkpoint markers) ↑ DNA damage (R→G) ↔ or repaired (G) R, G Checkpoint stress Interpreted as ROS-mediated consequence; reported as increased damage markers in some translational datasets
10 LDH / glycolytic vulnerability ↓ LDH performance / ↓ glycolytic flux (R→G) ↔ metabolic flexibility R, G Metabolic choke Cancer glycolysis becomes unstable when NADH/NAD+ and redox buffering are stressed
11 TrxR / thioredoxin system overload ↓ reserve (R→G) ↔ preserved R, G Parallel antioxidant collapse Useful when GSH data are mixed; TrxR can be the limiting system under sustained ROS 
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.
TumCI, Tumor Cell invasion: Click to Expand ⟱
Source:
Type:
Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms:

1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion.

2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue.

3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment.

4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream.

5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body.

6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection.

7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs.

8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis.
Scientific Papers found: Click to Expand⟱
516- MFrot,  immuno,  MF,    Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- vitro+vivo, GBM, U87MG
TumCP↓,
Apoptosis↑,
TumCMig↓,
ROS↑, treatment with OM-100 led to an increase in intracellular ROS levels
PD-L1↑, upregulating PD-L1 expression, thereby enhancing the efficacy of anti-PD-1 immunotherapy
TumVol↓, in mice
eff↑, enhance the efficacy of anti‑PD‑1 immunotherapy in vivo
*toxicity∅, OM-100 did not result in noteworthy changes in the blood routine parameters (Gran, HCT, HGB, Lymph, MCH, MCV, PLT, RBC, MPV, and WBC) and biochemical indicators (ALT, AST, T-BIL, CREA, TG, TC, HDL-c, and LDL-c) in normal mice
eff↑, Particularly, there was a more pronounced response to anti-PD-1 therapy in patients whose tumors expressed PD-L1 3
*toxicity∅, OM-100 treatment in healthy mice showed no adverse effects, indicating its safety for normal tissues.
Dose↝, 24-day treatment with a magnetic field intensity of 1.066 mT and a frequency of 100 kHz (figure shows motor driven 120Hz, 7200rpm pulsed
tumCV↓, anti-tumor efficacy of OM-100 treatment, which by impairing cell viability, increasing apoptosis, inhibiting cell migration, and invasion capabilities, as well as promoting oxidative stress.
TumCI↓,

5242- MFrot,    Rotating magnetic field downregulating type XI collagen to suppress triple-negative breast cancer metastasis by inactivating the ITGB1/FAK/YAP signaling pathway
- in-vitro, BC, NA
TumCI↓, RMF can significantly inhibit the invasion and metastasis of TNBC cells.
COL11A1↓, Notably, COL11A1 was reduced following exposure to RMF.
TumCG↓, both COL11A1 siRNA and RMF effectively suppressed tumor growth and lung metastasis, an effect reversed by ITGB1 agonist.
TumMeta↓,
ITGB1↓, suppress triple-negative breast cancer metastasis by inactivating the ITGB1/FAK/YAP signaling pathway
FAK↓,
YAP/TEAD↓,
Dose↝, we selected two magnetic field frequencies (2.5 and 5 Hz) and three magnetic induction intensities (0.04, 0.2, and 0.41 T) for investigation.

205- MFrot,  MF,    Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis
- vitro+vivo, BC, MDA-MB-231
OS↑, 31-46% prolonged survival
F-actin↓, decrease F-actin formation in vitro and in vivo
TumCI↓,
TumCMig↓, >4.5hrs
Rho↓,
selectivity↑, F-actin in noncancerous breast cells is much less sensitive than that in breast cancer cells, which indicate that the normal cells in our human bodies are less likely to be agitated by these magnetic fields.
TumMeta↓, Using an intermittent treatment modality, low-frequency rotating magnetic fields could significantly reduce mouse breast cancer metastasis, prolong mouse survival by 31.5 to 46.0% (P < 0.0001), and improve their overall physical condition.


* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   YAP/TEAD↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Migration ⓘ

COL11A1↓, 1,   F-actin↓, 1,   FAK↓, 1,   ITGB1↓, 1,   Rho↓, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 1,   TumMeta↓, 2,  

Immune & Inflammatory Signaling ⓘ

PD-L1↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 2,   eff↑, 2,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

PD-L1↑, 1,  

Functional Outcomes ⓘ

OS↑, 1,   TumVol↓, 1,  
Total Targets: 21

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

toxicity∅, 2,  
Total Targets: 1

Scientific Paper Hit Count for: TumCI, Tumor Cell invasion
3 Magnetic Field Rotating
2 Magnetic Fields
1 immunotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:192  Target#:324  State#:%  Dir#:%
  wNotes=on  sortOrder:rid,rpid

 

Home Page